English
Back
Open Account
港股窩輪Jenny
wrote a post · Apr 15 14:15

China Life shows a technical rebound and recovery, with a short-term challenge at the key resistance level of 28 yuan

Looking at the overall performance of the domestic insurance sector, there was evident divergence this morning (April 15). $CHINA LIFE (02628.HK)$
It is the only individual stock in the sector that recorded gains, while $PING AN (02318.HK)$、 $CPIC (02601.HK)$、 $CHINA TAIPING (00966.HK)$and $NCI (01336.HK)$ all showed declines to varying degrees.
In terms of technical signals, the overall sentiment in the sector is leaning bearish. Apart from New China Life Insurance receiving a 'Buy' signal, the remaining three major domestic insurance stocks have received 'Sell' signals, indicating that the system generally holds a bearish view on their short-term trends, suggesting profit-taking pressures. This highlights that China Life's current 'strong rebound and recovery' trend has relative independence within the sector. However, from a medium to long-term perspective, most individual stocks in the sector (including China Life) remain below the key MA60 line, indicating that the sector’s medium-term downtrend has not fundamentally reversed, and the current rally is still largely viewed as a technical rebound.
Looking at the overall performance of the domestic insurance sector, there was evident divergence this morning (April 15). $CHINA LIFE (02628.HK)$ It is the only individual stock in the sector that recorded gains, while $PING AN (02318.HK)$、 $CPIC (02601.HK)$、 $CHINA TAIPING (00966.HK)$and $NCI (01336.HK)$ all showed declines to varying degrees. In terms of technical signals, the overall sentiment in the sector is bearish. Apart from Xinhua Insurance receiving a 'Buy' signal, the remaining three major domestic insurance stocks received 'Sell' signals, reflecting a generally negative short-term outlook by the system and suggesting profit-taking pressure. This highlights the relatively independent nature of China Life's current 'strong rebound recovery' trend within the sector. However, from a medium-to-long term perspective, most stocks in the sector (including China Life) remain below the key MA60 line, indicating that the overall sector’s medium-term downtrend has not fundamentally reversed, and the current rise is still largely considered a technical rebound. China Life is currently trading at 27.54 yuan, up slightly by 0.15%. From a trend perspective, the stock price had repeatedly declined from its high of 36.16 yuan and remained under pressure, recently dipping as low as 23.74 yuan before finding significant support. It then gradually recovered, now returning to around 27.50 yuan. This indicates that buying interest at lower levels has indeed improved, transitioning from the previous weak decline into a rebound recovery phase...
China Life is currently trading at 27.54 yuan, up slightly by 0.15%. From a trend perspective, the stock price had repeatedly declined from a high of 36.16 yuan and remained under pressure, recently finding significant support only after dipping to 23.74 yuan, before gradually recovering to around 27.50 yuan. This indicates that buying interest at lower levels has indeed improved, shifting the stock from a previous weak decline into a rebound and recovery phase, with early signs of stabilizing and gradually challenging key resistance levels.
Looking at the overall performance of the domestic insurance sector, there was evident divergence this morning (April 15). $CHINA LIFE (02628.HK)$ It is the only individual stock in the sector that recorded gains, while $PING AN (02318.HK)$、 $CPIC (02601.HK)$、 $CHINA TAIPING (00966.HK)$and $NCI (01336.HK)$ all showed declines to varying degrees. In terms of technical signals, the overall sentiment in the sector is bearish. Apart from Xinhua Insurance receiving a 'Buy' signal, the remaining three major domestic insurance stocks received 'Sell' signals, reflecting a generally negative short-term outlook by the system and suggesting profit-taking pressure. This highlights the relatively independent nature of China Life's current 'strong rebound recovery' trend within the sector. However, from a medium-to-long term perspective, most stocks in the sector (including China Life) remain below the key MA60 line, indicating that the overall sector’s medium-term downtrend has not fundamentally reversed, and the current rise is still largely considered a technical rebound. China Life is currently trading at 27.54 yuan, up slightly by 0.15%. From a trend perspective, the stock price had repeatedly declined from its high of 36.16 yuan and remained under pressure, recently dipping as low as 23.74 yuan before finding significant support. It then gradually recovered, now returning to around 27.50 yuan. This indicates that buying interest at lower levels has indeed improved, transitioning from the previous weak decline into a rebound recovery phase...
In terms of the moving average system, China Life's current price has clearly moved above the 5-day line at 26.86 yuan, the 10-day line at 25.85 yuan, and the 20-day line at 26.73 yuan, while also approaching the 30-day line near 27.60 yuan. This suggests that the short-term structure has shifted from weakness to stability, and the rebound has some sustainability. However, there remains medium-term pressure from the 120-day line at 28.77 yuan and the 60-day line at 30.54 yuan. Thus, although short-term recovery is evident, until the price surpasses the range of 28.8 to 30.5 yuan, this should still be considered a corrective rally rather than a full resumption of a medium-term uptrend.
In terms of the Bollinger Bands, the middle band is around 26.73 yuan, the upper band is approximately 29.63 yuan, and the lower band is about 23.82 yuan. The current price of 27.50 yuan has risen above the middle band, reflecting that the stock price has returned from its previously weak zone to the upper-middle part of the channel, showing clear improvement in short-term sentiment. This indicates that the market is no longer merely passively arresting the decline but has started to actively recover. If the price can continue to hold above the middle band at 26.73 yuan and further approach or even break through the 27.6 to 28 yuan region, the rebound could gain further momentum; conversely, if it falls back below the middle band, the entire upward movement may still just be a technical rebound within the lower range.
In terms of momentum, the short-term RSI is around 67.8, while the medium-term RSIs are approximately 51.9 and 46.7, indicating that short-term momentum has clearly strengthened and is nearing the upper limit of the strong zone. This typically means that the stock price will continue to rise due to inertia, but if there is another sharp increase without a corresponding surge in trading volume, caution should be exercised for potential consolidation at higher levels. In terms of trading volume, the previous day (the 14th) saw about 57.39 million shares traded, aligning with a price-volume pattern, showing that this round of rebound is not entirely unsupported but is backed by some capital gradually accumulating at lower levels.
Market chatter actually reflects the current situation quite well. @ModelAndy Lau believes that as long as the stock holds steady above 27.08 yuan or even near the 26.44 yuan low, there is a chance for a V-shaped rebound, which closely aligns with the chart since the area around 27 yuan is indeed a key short-term defensive zone.@贏輸都要平常心The next target mentioned is 28 yuan, which is technically relevant because the 27.6 to 28 yuan range represents the first critical resistance level. If this can be broken, market expectations for testing 28.77 yuan will rise.
On the other hand, there are also many cautious voices in the market. @股海浮沈30年It was mentioned that 28 yuan is still not safe, which makes sense because until the resistance is effectively broken, any rebound may still see a tug-of-war at higher levels.@阿西巴sLooking directly down to 25 yuan, such bearish scenarios have not completely disappeared at this stage, especially if the price subsequently breaks below 26.7 yuan or even 26 yuan, market sentiment will significantly weaken. @winci’s question about whether to buy now reflects the common dilemma many investors face with such bottom-repairing stocks: acknowledging an improving trend but worrying about buying ahead of resistance.
From a short-term deployment perspective, the first support level can be seen at HKD 27.00 to 26.70, which is near the current price overlapping with the Bollinger Band's middle rail and the 20-day line; further support lies at HKD 25.80 to 26.00. In terms of resistance, the first resistance zone is at HKD 27.60 to 28.00, followed by HKD 28.77, and then HKD 29.60 to 30.50. This indicates that while China Life has rebounded from its lows, it is still in the early stages of challenging resistance levels and hasn't yet reached the top of the major resistance area. Therefore, the risk-reward ratio remains moderately positive. If the price can stabilize above HKD 26.70 and break through HKD 27.60 to 28.00, the risk-reward remains reasonable. However, blindly chasing higher prices before an effective breakout could lead to pullbacks due to resistance.
In summary, China Life is currently in a strong rebound recovery pattern after bouncing back from its lows. The short-term technical picture has improved and it is beginning to enter a phase where it challenges medium-term resistance. Investors can maintain a slightly positive view, but the key focus remains whether the price can break through HKD 27.60 to 28.00. If there is a successful breakout accompanied by increased trading volume, the rebound could extend to HKD 28.80 or even HKD 29.60. However, if it fails to break through and drops below HKD 26.70 again, the price is likely to retreat into a consolidation range.
Based on the above analysis, the strategies for deployment can be divided into the following main approaches:
$UB#CLIFERC2808E.C (53359.HK)$$SG#CLIFERC2612B.C (53213.HK)$
$HSCLIFE@EC2609C.C (27795.HK)$$BPCLIFE@EP2606A.P (24212.HK)$
Looking at the overall performance of the domestic insurance sector, there was evident divergence this morning (April 15). $CHINA LIFE (02628.HK)$ It is the only individual stock in the sector that recorded gains, while $PING AN (02318.HK)$、 $CPIC (02601.HK)$、 $CHINA TAIPING (00966.HK)$and $NCI (01336.HK)$ all showed declines to varying degrees. In terms of technical signals, the overall sentiment in the sector is bearish. Apart from Xinhua Insurance receiving a 'Buy' signal, the remaining three major domestic insurance stocks received 'Sell' signals, reflecting a generally negative short-term outlook by the system and suggesting profit-taking pressure. This highlights the relatively independent nature of China Life's current 'strong rebound recovery' trend within the sector. However, from a medium-to-long term perspective, most stocks in the sector (including China Life) remain below the key MA60 line, indicating that the overall sector’s medium-term downtrend has not fundamentally reversed, and the current rise is still largely considered a technical rebound. China Life is currently trading at 27.54 yuan, up slightly by 0.15%. From a trend perspective, the stock price had repeatedly declined from its high of 36.16 yuan and remained under pressure, recently dipping as low as 23.74 yuan before finding significant support. It then gradually recovered, now returning to around 27.50 yuan. This indicates that buying interest at lower levels has indeed improved, transitioning from the previous weak decline into a rebound recovery phase...
Looking at the overall performance of the domestic insurance sector, there was evident divergence this morning (April 15). $CHINA LIFE (02628.HK)$ It is the only individual stock in the sector that recorded gains, while $PING AN (02318.HK)$、 $CPIC (02601.HK)$、 $CHINA TAIPING (00966.HK)$and $NCI (01336.HK)$ all showed declines to varying degrees. In terms of technical signals, the overall sentiment in the sector is bearish. Apart from Xinhua Insurance receiving a 'Buy' signal, the remaining three major domestic insurance stocks received 'Sell' signals, reflecting a generally negative short-term outlook by the system and suggesting profit-taking pressure. This highlights the relatively independent nature of China Life's current 'strong rebound recovery' trend within the sector. However, from a medium-to-long term perspective, most stocks in the sector (including China Life) remain below the key MA60 line, indicating that the overall sector’s medium-term downtrend has not fundamentally reversed, and the current rise is still largely considered a technical rebound. China Life is currently trading at 27.54 yuan, up slightly by 0.15%. From a trend perspective, the stock price had repeatedly declined from its high of 36.16 yuan and remained under pressure, recently dipping as low as 23.74 yuan before finding significant support. It then gradually recovered, now returning to around 27.50 yuan. This indicates that buying interest at lower levels has indeed improved, transitioning from the previous weak decline into a rebound recovery phase...
For more market analysis, stay tuned to Jenny's daily updates on 'Hong Kong Stock Warrants'!
Reminder: This article does not constitute any investment advice.
This article is for reference only and does not constitute any investment advice. The market data, opinions, and analysis contained herein may change at any time without prior notice. We are not responsible for any loss or damage caused by reliance on the information in this article. Technical analysis only shows whether certain technical conditions are met; a comprehensive assessment of asset performance should be conducted using additional data. Decisions to trade should not be based solely on this article. Please note that past performance is not indicative of future results.
#HKStocks #ChinaLifeInsurance #Real-TimeAnalysis #WarrantPick #WarrantGuide #DerivativesHedging #HKWarrantsJenny #Blue-ChipStocks #TechnicalAnalysis
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Thumbs Up
3
154K Views
Report
Comment (1)
Write a Comment...
1
3